TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company focused on immuno-oncology and RNA-based therapies, announced that it has entered into a financing agreement with an institutional healthcare investor for up to $20 million. The arrangement includes up to $6 million in pre-paid advances and a three-year Standby Equity Purchase Agreement allowing the company to sell up to $14 million in common stock. This financial flexibility is intended to support its Phase 2a trial of lead candidate TTX-MC138 and ongoing operations.
The financing comes as TransCode prepares to advance TTX-MC138, a therapeutic candidate targeting metastatic tumors that overexpress microRNA-10b, a unique and well-documented biomarker of metastasis. The company’s pipeline includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The additional capital will be crucial for conducting the Phase 2a trial, which aims to further evaluate the safety and efficacy of TTX-MC138 in patients with advanced cancer.
This agreement underscores investor confidence in TransCode's approach to addressing high-risk and advanced cancers through RNA-based therapeutics. The Standby Equity Purchase Agreement provides the company with the ability to access additional funds over time, enabling it to adapt to evolving research needs and operational requirements. As a clinical-stage company, securing such financing is vital for sustaining research momentum and moving closer to potential regulatory milestones.
For more details, the full press release is available at https://ibn.fm/Zz7jW. Updates regarding TransCode Therapeutics can be found in the company's newsroom at https://ibn.fm/RNAZ.
